A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

NCT00998764 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

494

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.

Conditions

Alzheimer Disease

Interventions

DRUG: Bapineuzumab 0.5 mg/kg

Sponsor

Pfizer